Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Halperin

Showing results (471-480 of 544) with videos related to

Pageof 55
Sort By:
Vaccine|December 8, 2010
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of ageFrancisco Diaz-Mitoma, Scott A Halperin, Bruce Tapiero, et al.
Journal of the Pediatric Infectious Diseases Society|September 4, 2015
Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialJoanne M Langley, Long Wang, Naresh Aggarwal, et al.
BMC Geriatrics|February 18, 2025
Unveiling the impact: understanding long-term care workers' experiences and their perceptions of resident challenges amidst the COVID-19 pandemicDonna M Halperin, Krista Whitfield, Julie A Bettinger, et al.
Vaccine|March 5, 2026
Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infectionGuillermo M Ruiz-Palacios, Pedro Enrique Cahn, Scott A Halperin, et al.
Vaccine|June 24, 2020
Assessing the completeness of infant and childhood immunizations within a provincial registry populated by parental reporting: A study using linked databases in Ontario, CanadaSarah E Wilson, Andrew S Wilton, Jacqueline Young, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
The Pediatric Infectious Disease Journal|January 30, 2022
Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance NetworkYousif Murad, Te-Yu Hung, Manish Sadarangani, et al.
The Lancet. Infectious Diseases|April 24, 2017
Maternal immunisation: collaborating with mother natureArnaud Marchant, Manish Sadarangani, Mathieu Garand, et al.
Emerging Infectious Diseases|February 25, 2020
Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada<sup>1</sup>Joanne M Langley, Soren Gantt, Caroline Quach, et al.
Vaccine|November 26, 2011
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous doseScott A Halperin, David Scheifele, Gaston De Serres, et al.
Pageof 55

Showing results (471-480 of 544) with videos related to

Sort By:
Pageof 55
Vaccine|December 8, 2010
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of ageFrancisco Diaz-Mitoma, Scott A Halperin, Bruce Tapiero, et al.
Journal of the Pediatric Infectious Diseases Society|September 4, 2015
Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialJoanne M Langley, Long Wang, Naresh Aggarwal, et al.
BMC Geriatrics|February 18, 2025
Unveiling the impact: understanding long-term care workers' experiences and their perceptions of resident challenges amidst the COVID-19 pandemicDonna M Halperin, Krista Whitfield, Julie A Bettinger, et al.
Vaccine|March 5, 2026
Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infectionGuillermo M Ruiz-Palacios, Pedro Enrique Cahn, Scott A Halperin, et al.
Vaccine|June 24, 2020
Assessing the completeness of infant and childhood immunizations within a provincial registry populated by parental reporting: A study using linked databases in Ontario, CanadaSarah E Wilson, Andrew S Wilton, Jacqueline Young, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
The Pediatric Infectious Disease Journal|January 30, 2022
Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance NetworkYousif Murad, Te-Yu Hung, Manish Sadarangani, et al.
The Lancet. Infectious Diseases|April 24, 2017
Maternal immunisation: collaborating with mother natureArnaud Marchant, Manish Sadarangani, Mathieu Garand, et al.
Emerging Infectious Diseases|February 25, 2020
Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada<sup>1</sup>Joanne M Langley, Soren Gantt, Caroline Quach, et al.
Vaccine|November 26, 2011
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous doseScott A Halperin, David Scheifele, Gaston De Serres, et al.
Pageof 55